Jupiter Asset Management Ltd. Sells 779,802 Shares of Novavax, Inc. $NVAX

Jupiter Asset Management Ltd. trimmed its position in Novavax, Inc. (NASDAQ:NVAX) by 88.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 100,608 shares of the biopharmaceutical company’s stock after selling 779,802 shares during the quarter. Jupiter Asset Management Ltd. owned approximately 0.06% of Novavax worth $872,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of NVAX. AQR Capital Management LLC increased its position in Novavax by 95.2% during the first quarter. AQR Capital Management LLC now owns 44,427 shares of the biopharmaceutical company’s stock worth $285,000 after buying an additional 21,663 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Novavax by 2.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 104,562 shares of the biopharmaceutical company’s stock worth $678,000 after acquiring an additional 2,750 shares during the period. Caxton Associates LLP acquired a new position in shares of Novavax during the 1st quarter worth approximately $158,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Novavax by 16.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 312,789 shares of the biopharmaceutical company’s stock valued at $2,005,000 after acquiring an additional 44,105 shares during the period. Finally, Strs Ohio acquired a new stake in Novavax during the 1st quarter valued at $167,000. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

NVAX has been the topic of several research reports. Wall Street Zen downgraded shares of Novavax from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. BTIG Research reiterated a “buy” rating and issued a $19.00 price target on shares of Novavax in a research note on Tuesday, January 20th. Weiss Ratings reissued a “sell (d+)” rating on shares of Novavax in a report on Monday, December 29th. TD Cowen reduced their price objective on Novavax from $8.00 to $7.00 and set a “hold” rating for the company in a report on Tuesday, November 4th. Finally, JPMorgan Chase & Co. decreased their target price on Novavax from $7.00 to $6.00 and set an “underweight” rating on the stock in a research report on Tuesday, November 18th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $11.25.

Novavax Price Performance

Shares of Novavax stock opened at $9.20 on Monday. The company has a quick ratio of 2.24, a current ratio of 2.27 and a debt-to-equity ratio of 5.93. The stock has a market capitalization of $1.50 billion, a price-to-earnings ratio of 5.14 and a beta of 2.58. Novavax, Inc. has a twelve month low of $5.01 and a twelve month high of $10.64. The company has a 50-day simple moving average of $8.01 and a two-hundred day simple moving average of $7.97.

Novavax Profile

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.